PRI Board of Director members elects Eleni Tsompanidou as New President

The regulatory landscape must be guided by scientific evidence and evolve at an accelerated pace to foster innovation. As a neutral and independent organization, that brings together developers, microbiome experts and service providers, PRI is well-positioned to support innovation and new product developments by carving the regulatory pathways while ensuring that safety remains uncompromised. PRI’s “share and learn” approach promotes a more integrated and comprehensive strategy for all product developments related to the microbiome. Rather than creating isolated regulatory pathways that may lead to unintended challenges, leveraging insights from adjacent fields will accelerate progress and facilitate successful product development. I am therefore, privileged to support the PRI on this mission and to succeed Sandrine Claus as the new President. Sandrine, together with Céline Druart, the Executive Director, have reshaped PRI’s mission ensuring its continuous success. I am thankful that Sandrine will remain in the executive committee as Secretary. I am also equally thankful to the fact that the executive committee is complemented by talented and knowledgeable individuals: Gianfranco Grompone, Sylvie Binda and Stanislas Desjonquères. This committee brings together past experience from Sandrine and Stanislas and complements this with the commitment of new, to the executive committee, members. Together we are committed to continue offering the support that Céline and her team need to continue serving the PRI members.

Eleni Tsompanidou, Winclove Probiotics

It has been an immense honor to serve as President of the PRI, and I am incredibly pleased to pass the torch to Eleni as the new President. Her expertise in the microbiome field and great leadership skills will ensure that the organisation continues to thrive. I am eager to continue supporting the PRI’s mission and working alongside Eleni as we expand our scope of activities to embrace the full diversity of microbiome-derived products. 

Sandrine Claus, Starfish Bioscience

As the regulatory context around microbiome-based products is being impacted by new important pieces of legislation, this momentum is key for PRI, as expert of regulatory science, but also for other associations. My key role here at PRI would be to ensure that we are in a collaboration spirit with others to have our voices heard by regulatory bodies but also expert communities of this so exciting innovation area based on the microbiome as a reservoir for new biotherapies, diagnosis tools and clinical biomarkers recognition.

Sylvie Binda, Lallemand Health Solutions

It’s a true pleasure and honor for me to join the team of the new PRI executive committee. Transforming the science of the microbiome into new therapies and products which will improve people’s life is probably one of the most fascinating challenges to focus on in the coming years. As an active member of the new elected executive team, I will put all my passion and efforts into articulating microbiome-driven innovation and recent scientific discoveries with the regulatory bodies and authorities, helping to create positive bridges between these two worlds, following the “share and learn” philosophy.

Gianfranco Grompone, BioGaia